Ligand Appoints Dr. Nancy Gray to its Board of Directors
Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology
Ligand Reports Second Quarter 2017 Financial Results
Ligand to Report Second Quarter 2017 Results on August 7th
Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330
Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology
Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix
Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences
